View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 27, 2021

Reven’s anti-sepsis drug provides rapid recovery in Covid-19 trial

Based on the latest clinical data, the DCMB approved the commencement of the randomised, double-blind part 2 of the Phase II trial.

Reven has concluded the initial part of the Phase I/II clinical trial of its lead anti-sepsis drug candidate, RJX, which showed rapid recovery in hospitalised Covid-19 patients at increased risk.

RJX is an intravenous (IV) formulation of a peculiar combination of anti-oxidant and anti-inflammatory ingredients.

It is being developed as a potential therapy for patients with sepsis, including Covid-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS).

Part one of the two-part, two-cohort, multicentre trial enrolled 12 hospitalised adult patients with symptomatic high-risk Covid-19 pneumonia and abnormally raised inflammation markers in the blood.

Subjects were given daily IV doses of RJX plus standard of care.

Findings showed that nine out of the 12 subjects, including three with hypoxemic respiratory failure, demonstrated quick clinical recovery with normalisation of the blood oxygen levels and abnormally raised inflammation markers.

These subjects were discharged from the hospital between three to 14 days with a median of five days.

Furthermore, RJX infusion was well tolerated in all subjects, with no side effects reported in the trial.

On reviewing the clinical data from 12 subjects, the Independent Data and Safety Monitoring Board (DSMB) granted approval to commence the randomised, double-blind part two portion of the Phase II study.

Reven chief medical officer and chief scientific officer Fatih Uckun said: “Since RJX is a potent anti-oxidant and anti-inflammatory agent that has been shown to reduce the tissue-level oxidative stress in multiple organs in animal models of septic shock, cytokine storm, and multiorgan failure, we are hopeful that it will contribute to the prevention of progression of Covid-19 and its faster resolution in high-risk patients with viral sepsis.”

Latest studies in animal models of sepsis, cytokine storm, ARDS and multiorgan failure, offered scientific proof of concept that RJX can prevent and reverse acute lung and liver injury linked to sepsis and cytokine storm.

The drug also showed to enhance the survival outcome at a dose level more than ten times lesser than its maximum tolerated dose for humans.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy